Navigation Links
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Date:11/27/2012

ngs us one step closer towards achieving this objective."

The Phase 2 study is expected to enroll at least 45 adult patients undergoing dUCBT for the treatment of hematologic malignancies.  Patients will be randomized, with a ratio of 2:1, to receive either ProHema plus an unmanipulated cord blood unit or two unmanipulated cord blood units.  The study will evaluate time to neutrophil and platelet recovery, incidence of serious infections and graft-versus-host disease, 100-day mortality and relative dominance of ProHema over the unmanipulated cord in contributing to reconstitution.  Results are expected in 2013.

"The preclinical and clinical data obtained to date suggest that ProHema may address several of the unmet medical needs in the evolving field of hematopoietic stem cell transplantation," said Steven Devine, M.D., Professor of Medicine and Program Director of the Blood and Marrow Transplant Program at the Ohio State University and a principal investigator of the Phase 2 clinical study.  "While further investigation is required, an intervention that enables early and durable reconstitution of the best-HLA-matched cord blood unit has the potential to improve patient outcomes and substantially enhance the therapeutic value proposition of cord blood transplant."

About ProHema

ProHema is an innovative cord blood-derived cell therapy containing pharmacologically-modulated hematopoietic stem cells (HSCs).  ProHema is produced through a proprietary, two-hour, ex vivo cell modulation process that results in rapid activation of key biological pathways involved in homing, proliferation and survival of HSCs.  In preclinical testing, ProHema has demonstrated the potential to accelerate engraftment and to drive durable hematopoietic reconstitution, without the need for multi-week expansion protocols.  In an initial Phase 1b study in adult patients with hematologic malignancies undergoing double umbilical
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
3. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
4. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
5. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
6. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
7. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
8. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
9. Echo Therapeutics Announces Third Quarter 2012 Financial Results
10. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
11. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Pomerantz LLP has filed ... the "Company") (NASDAQ: EDAP ) and certain ... States District Court, Southern District of New ... behalf of a class consisting of all persons or ... and July 30, 2014, inclusive (the "Class Period"). This class ...
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 Research ... CNS Disorders Drug Pipeline Insight 2014" report to their ... market in US is one of the largest segments of ... an alarming rate, while the available therapies were unable to ... growth in the market for CNS disorder, especially over the ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... Sept. 21, 2011 Boehringer Ingelheim,s investigational tyrosine kinase ... reducing lung function decline in patients with idiopathic pulmonary ... published today online in the New England Journal ... progressive and severely debilitating lung disease with a high ...
... CHAPEL HILL, N.C., Sept. 21, 2011 Pharmaceutical ... support a variety of product-related initiatives, from treatment ... playing such a pivotal role in a product,s ... use of Health Outcomes data. To ...
Cached Medicine Technology:New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 2New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 3New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 4New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 5Optimizing the Use of Health Outcomes Data in the Marketplace 2
(Date:8/30/2014)... Daily Gossip magazine reveals in its "Panic Away" ... under control with a simple and efficient method. , ... new method as an anxiety recovery program which promises ... anxiety related disorders. , What makes this program ... can be accessed by users from the comfort of ...
(Date:8/30/2014)... Scotch Plains, NJ (PRWEB) August 30, 2014 ... the first facilities in New Jersey and even in ... in-demand technology that takes inches off of patients’ waists ... by freezing cells in small sections, Vanquish is more ... without pain. Patients lay comfortably under panels about ...
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... introduced low cost SEO service for small businesses. , ... or start-ups cannot afford costly search engine optimization service. ... budget of small businesses into account. , On ... said, “We have introduced this low cost SEO service ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Acne is a common problem millions of American cope with ... a daily nuisance, for some, it can have a crippling impact ... lead to dramatic mood swings and depression. , Those struggling ... their skin. In some cases, that can make the problem even ... those on a quest for clearer skin can now view ...
Breaking Medicine News(10 mins):Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
... first study of its kind, 161 postnatal women with ... groups to test the effect of a physiotherapist-led exercise ... group received an eight-week "Mother and Baby" program, including ... with parenting education. In the second group, ...
... University of Delaware have developed a new method for ... other diseases., Developed by Zhihao Zhuang, UD assistant professor ... chemical method yields hundredsfold more ubiquitylated proteins than current ... such mysteries as how cancer cells gain resistance to ...
... ... technology with the launch of their new web based clinical Label Approval System - ... ... continue to showcase innovative technology with the launch of their new web based clinical ...
... is available in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-04/aaoo-amb032510.php,">Chinese . ... where very thin needles are used to stimulate ... therapeutic responses, may be an effective treatment option ... olfactory dysfunction (PVOD), according to new research in ...
... and unemployment rates that are nearly double that of ... to make less use of public assistance, especially childcare ... Policy Program. OSU researchers Deana Grobe and Bobbie ... Minnesota, found that the rates of use of such ...
... than one in four elderly Americans lacked the capacity to make ... to a study of 3,746 people to be published April 1 ... who had advance directives - including living wills or durable powers ... of the time, says lead author Maria Silveira, M.D., M.P.H., physician ...
Cached Medicine News:Health News:New mums beat the blues and increase wellbeing with physio exercise, study reveals 2Health News:UD team develops new method for producing proteins critical to medical research 2Health News:Almac to Improve Label Approval Process in Clinical Trials 2Health News:Almac to Improve Label Approval Process in Clinical Trials 3Health News:Acupuncture may be an effective treatment for post-viral infection loss of smell 2Health News:Despite much-higher poverty rates, rural Oregonians use less public assistance 2Health News:Despite much-higher poverty rates, rural Oregonians use less public assistance 3Health News:More than one-quarter of elderly patients lack decision-making capacity at death 2Health News:More than one-quarter of elderly patients lack decision-making capacity at death 3
... Pipette Tracker Pro is the only pipette calibration ... regulated environment with the tools that they need ... All of the features of Pipette Tracker ... Full audit trail implementation Support for Oracle ...
... V-shaped bottom allows easy withdrawal of ... per bag, ,• Corner pouring lips ... Basin designed for 4, 8, and 12 ... bottom permits withdrawal of practically all of ...
Reservoir, High Profile, Multi Well, 12 Row, Pyramid Bottom, 21mL Available Sterile...
Reservoir, High Profile, Single Well, 96ch-format, Pyramid Bottom, 240mL Available Sterile...
Medicine Products: